Merck & Co.: Running A Bit Hot


  • Merck has seen a significant valuation re-rating take place over the past years.
  • This comes amidst the success of Keytruda, which creates some dependency risks as well.
  • With no growth seen in 2023, amidst tough comparables from a pandemic-related contribution in 2022, I am a bit cautious here, as shares keep riding higher.

Merck Annouces Job Cuts

Marko Georgiev

Late in October, I concluded that Merck (NYSE:MRK) was a great medicine for the portfolio, as it has seen strong growth, even after stripping out the “contribution” from the pandemic.

Growth has resulted in an uptick in the

Disclosure: I/we have a beneficial long position in the shares of MRK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I have trimmed my long position here.

If you like to see more ideas, please subscribe to the premium service “Value in Corporate Events” here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!

Leave a Reply

Your email address will not be published. Required fields are marked *